Spastic Paraplegia 21 (SPG21) (N-Term) Peptide
SPG21
Reactivity: Human
Host: Synthetic
BP, WB
Catalog No. ABIN5671444
$160.46
Plus shipping costs $50.00
100 μg
Shipping to:
United States
Delivery in 11 to 17 Business Days
Quick Overview for Spastic Paraplegia 21 (SPG21) (N-Term) Peptide (ABIN5671444)
Target
SPG21
(Spastic Paraplegia 21 (SPG21))
Origin
Human
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- N-Term
-
Sequence
- GTVPLKKIIV DDDDSKIWSL YDAGPRSIRC PLIFLPPVSG TADVFFRQIL
-
Characteristics
- This is a synthetic peptide designed for use in combination with anti- SPG21 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Storage
- -20 °C
-
Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- SPG21 (Spastic Paraplegia 21 (SPG21))
-
Background
-
The protein encoded by this gene binds to the hydrophobic C-terminal amino acids of CD4 which are involved in repression of T cell activation. The interaction with CD4 is mediated by the noncatalytic alpha/beta hydrolase fold domain of this protein. It is thus proposed that this gene product modulates the stimulatory activity of CD4. Mutations in this gene are associated with autosomal recessive spastic paraplegia 21 (SPG21), also known as mast syndrome. Alternative splicing results in multiple transcript variants.
Alias Symbols: MAST, ACP33, GL010, BM-019
Protein Size: 281 -
Gene ID
- 51324
-
NCBI Accession
- NM_001127889, NP_001121361
Target
-
You are here:
